Top 50 Cell Line Development

Cytena develops single-cell printing technology and automated solutions for cell line development, enabling the efficient production of stable cell lines for therapeutic applications. Their systems streamline workflows for biopharmaceutical companies, reducing the time and cost associated with developing biologics while ensuring compliance with regulatory standards.

Great Bay Bio develops biopharmaceuticals using its AI-enabled platforms, AlfaCell and AlfaMedX, which streamline cell line development and optimize cell culture media. This technology reduces the time and complexity of producing high-yield, stable cell lines, addressing inefficiencies in traditional biologics development.

Opo Bio specializes in cell line development for the cultivated meat industry, providing a multi-species and multi-cell type bank that supports large-scale cell culture. By supplying optimized livestock cells, Opo Bio enables producers to enhance cultivation efficiency and reduce production costs for cultivated meat products.

64x Bio develops a high throughput genome engineering platform that accelerates the discovery of optimized mammalian cell lines for cell and gene therapies. This technology enables pharmaceutical and biotechnology companies to efficiently design and manufacture next-generation therapeutics, addressing the challenges of traditional cell line development.

Asimov develops a platform that integrates synthetic biology, biophysical simulations, and machine learning to engineer mammalian cell lines for the production of biologics and gene therapies. This technology enables healthcare companies to optimize the design and manufacturing processes of genetic circuits, improving efficiency and scalability in therapeutic applications.

Alvotech specializes in the development and manufacturing of biosimilars through a vertically integrated process that includes cell line development and fill-finish manufacturing. This approach enhances access to affordable biologic medicines, addressing the high costs associated with traditional biologic therapies.

Bit.bio develops a cell coding platform that utilizes deterministic programming to create and manufacture any human cell type with precision and scalability. This technology addresses the need for consistent and reliable cell production for research and therapeutic applications, enabling the development of next-generation treatments.

SIMABS NV has developed a continuous bioprocessing platform for the rapid and cost-effective development and GMP manufacturing of monoclonal and bispecific antibodies, addressing the need for high-quality biologics in personalized medicine. Their integrated approach offers a complete solution, including cell line development and regulatory support, enabling biopharmaceutical companies to accelerate their product development timelines while reducing costs.

The startup develops a DNA integration platform that enhances the engineering of cell lines for gene and cell therapies, specifically targeting the production of recombinant adeno-associated virus vectors. By improving viral vector yield and efficacy, the company enables biopharmaceutical firms to produce more effective therapies for serious diseases.

Wheeler Bio utilizes its Portable CMC® platform to streamline the transition from drug discovery to clinical supply by offering modular development services, including mammalian cell line and process development. This approach addresses the significant delays and risks associated with the traditional drug development pipeline, enabling biopharma companies to accelerate their path to IND filing.

Mytos is developing a fully automated platform for the manufacture of any human cell type, utilizing advanced robotics and software to streamline cell culture processes. This technology addresses the challenges of contamination and human error in cell production, enabling consistent, high-quality output at a scale that allows one technician to achieve the productivity of ten scientists working manually.

PDCline Pharma develops a proprietary allogeneic Plasmacytoid Dendritic Cell line pre-loaded with tumor-derived peptides to create off-the-shelf, antigen-specific immunotherapies for cancer treatment. This technology addresses the limitations of current dendritic cell therapies by providing a scalable and effective solution for inducing strong cytotoxic immune responses against various cancers, including lung cancer.

Roslin Technologies develops pluripotent animal stem cells for the cultivated meat industry, providing scalable cell lines that can differentiate into muscle and fat tissues. This technology addresses the growing global demand for sustainable protein by enabling the production of real meat without raising animals, thereby reducing environmental impact and improving animal welfare.

Somite.ai utilizes a proprietary digital twin of the embryo and machine learning to optimize protocols for generating somite-derived cells, which are essential for treating conditions like Duchenne muscular dystrophy and metabolic diseases. By leveraging big data, the company enhances the efficiency and scalability of cell replacement therapies, addressing the challenges of producing diverse human cell types.

The startup manufactures immune clinical cells to facilitate cell therapy development, utilizing specialized software tools for the design, production, and analysis of these therapies. Their integrated approach combines a dedicated manufacturing facility and a team of experts, enabling researchers to expedite the delivery of effective cell therapies to patients.

Antiverse utilizes machine learning and advanced cell line engineering to design target-specific antibody libraries for challenging drug targets, including G-protein coupled receptors and ion channels. The platform accelerates the antibody discovery process, enabling the development of functional therapeutics within six months, addressing the lengthy timelines typically associated with traditional drug development methods.

GC Therapeutics utilizes a "plug-and-play" induced pluripotent stem cell (iPSC) programming platform, TFome™, to efficiently generate various cell types for cell therapies. This technology addresses the challenges of scalability and accessibility in cell therapy development, enabling the rapid production of off-the-shelf iPSC-based medicines for gastrointestinal, neurological, and immunological diseases.

The startup has developed a fluid-shaping technology that replaces traditional microtiter plates with a microscale system for single-cell cloning, allowing researchers to expose cells to relevant experimental conditions. This technology enables multiple users to conduct simultaneous experiments efficiently, addressing the limitations of current cloning methods.

Astraveus is developing the Lakhesys - The Benchtop Cell Factory™, a microfluidics-powered platform that integrates hardware, software, and consumables for cell and gene therapy manufacturing. This solution enhances development throughput by up to 100 times while reducing resource consumption by 10 to 20 times, making cell therapies more accessible to patients.

Trailhead Biosystems develops iPSC-derived human cells for drug discovery and cell-based therapies, utilizing the High-Dimensional Design of Experiments (HD-DoE) platform to optimize cell growth and differentiation. Their products, such as the TrailBio® Endothelial Cell Kit and Pre-Myelinating Oligodendrocyte Kit, provide reliable solutions for vascular biology research and myelination studies, addressing the need for precise cellular models in regenerative medicine.

GeneFab provides contract development and manufacturing services for cell and gene therapies, utilizing expertise in gene-to-cell design and optimization to enhance product manufacturability. The company addresses the challenges faced by innovators in bringing novel therapies to clinical application by offering flexible tech operations and transparent project management throughout the drug development lifecycle.

Cellino is developing a scalable, automated biomanufacturing system that produces personalized cell therapies using patient-derived cells. This technology addresses the challenges of high costs and lengthy production times in delivering potentially curative treatments for individual patients.

Turbine's Simulated Cell™ platform utilizes AI to predict biological responses by simulating experiments across various models, including engineered cell lines and patient samples. This technology accelerates drug development by generating actionable insights in half the time of traditional methods, enabling researchers to identify optimal experimental pathways for novel cancer therapies.

Cell X Technologies develops the Celligent™ platform, which integrates robotics, imaging, and artificial intelligence to automate and optimize cell processing for stem cell research and cell manufacturing. This technology addresses the challenges of achieving consistent, reproducible, and GMP-compliant processes necessary for the commercialization of cellular therapies and tissue engineering applications.

The startup develops machine-learning tools to design cell factories capable of producing a wide range of products, including food, fabrics, and medicines. By simplifying the complex process of cellular manufacturing, the company aims to replace traditional farms and factories, promoting a more sustainable production model.

CellRep develops cell reprogramming strategies to enhance T cell functionality, increasing their therapeutic potential for cancer and chronic conditions. The company provides an end-to-end pipeline from target discovery to preclinical validation, enabling more effective cell therapies for patients.

Avigen is developing a platform to identify highly effective immune cells for use in cellular immunotherapies. This technology aims to accelerate the development of new therapies by pre-selecting potent cells, reducing risks and streamlining the process.

The startup operates a cell therapy research and manufacturing platform that enhances process control and scalability in autologous cell and gene therapy bioprocessing. By enabling parallel execution of cell culture conditions, the platform reduces manufacturing costs while improving efficiency in process development.

CellRev specializes in process intensification for cell manufacturing through advanced bioprocessing techniques that enhance yield and efficiency. The company reduces high production costs and lengthy timelines in biomanufacturing, facilitating faster and more cost-effective development of cell-based therapies.

Solaris Bio develops serum-free culture media and related solutions for cell manufacturing in regenerative medicine, utilizing proprietary AI technology to enhance the safety and efficacy of cell products while reducing costs. The startup addresses the need for chemically defined and animal origin-free media formulations that optimize cell growth and differentiation for various therapeutic applications.

The startup develops AI-driven live-cell imaging technology to predict and optimize stem cell differentiation, enabling the scalable manufacture of any cell or tissue in the body. This approach addresses the need for effective stem cell-based therapies for chronic diseases, facilitating data-driven drug development and improving patient outcomes.

CellFE develops a microfluidics-based device that delivers gene-editing molecules to enhance cell health and yield during the manufacturing of cell therapies. This technology addresses the challenges of long production times and high costs, enabling scalable and efficient processes from research to commercial applications.

HemostOD engineers and manufactures universal platelets from a stable megakaryocytic cell line using advanced microfluidic technologies, providing a scalable and rapid source of high-quality platelets. This technology addresses the need for effective treatments in patients with thrombocytopenia and facilitates targeted delivery of therapeutic agents in regenerative medicine applications.

Mekonos develops a proprietary cell-engineering platform that utilizes microfluidic technology to facilitate the creation of cell therapies on a chip. This approach enables precise manipulation of cellular environments, improving the efficiency and scalability of therapeutic development.

Cell Bauhaus develops a virtual cell technology platform that enables the computer-aided design and simulation of living systems, allowing researchers to optimize genetic constructs and cellular behavior before laboratory experimentation. This approach significantly reduces the time and cost associated with bringing synthetic biology products to market by minimizing trial and error in the development process.

Livestock Labs develops genetically engineered cell lines specifically for the cultivated meat industry, utilizing genetic engineering, data analytics, and machine learning to create stable and robust cell lines. Their offerings significantly reduce production costs and time for meat producers and research institutions, while ensuring optimal growth, flavor, and nutrition in cultivated meat products.

Saku Biosciences utilizes PicoShell technology, a lab-on-a-particle platform for directed cellular evolution, to lower the production costs of biotechnology products. The company offers contract services and cell strain products that enhance yield and efficiency in cell line development and strain engineering workflows.

Asimov provides a synthetic‑biology platform that combines GMP‑qualified CHO and HEK293‑derived host cell lines, a library of over 1,000 validated genetic parts, and the cloud‑based Kernel design software powered by AI models. The platform enables users to design and produce high‑titer biologics, lentiviral and AAV vectors either in‑house or via Asimov’s full‑service cell‑line development, reducing plasmid requirements, material costs, and development timelines. It targets biopharma companies, CDMOs, and academic groups developing therapeutic proteins and viral‑vector therapies.

Pluristyx develops induced pluripotent stem cells (iPSCs) and offers gene editing technologies, including their proprietary FailSafe® edit, to enhance the manufacturing process of cellular therapies. The company addresses challenges in the development and commercialization of regenerative medicine by providing end-to-end support and expertise throughout the product lifecycle.

Deco Labs develops enabling technologies for cellular agriculture, focusing on cell line development, genetic engineering, and bioprocess design to enhance production efficiency. The startup addresses cost, scale, and quality challenges in the industry by optimizing media formulation and biomaterial development.

BrainXell specializes in producing high-purity, iPSC-derived human neurons, astrocytes, and microglia for research and drug discovery in central nervous system disorders. The company provides customizable cell lines in various quantities, enabling researchers to advance their studies with precise, patient-derived cellular models.

CellVoyant develops AI-driven stem cell therapies specifically designed to treat chronic diseases by precisely manufacturing cells and tissues at scale. This technology addresses the need for effective, personalized treatments that can improve patient outcomes in the management of long-term health conditions.

Logomix offers a Geno-Writing platform that enables precise engineering of megabase-scale genomic sequences in human cells, facilitating the creation of custom cell types with specific functions. This technology addresses the challenges of immune rejection and functional integration in cell therapies, enhancing the development of advanced regenerative medicine solutions.

ScaleReady provides G-Rex® bioreactors and GMP raw materials to maintain cell phenotype consistency during the scale-up of cell and gene therapies. This technology addresses the challenge of cell phenotype drift, ensuring high-quality cell production from research to clinical applications.

This startup provides vector technology solutions for viral and non-viral payload delivery, offering services such as plasmid optimization, vector design, cell line development, gene editing, and preclinical viral production. They serve the cell and gene therapy markets, enabling advancements in therapeutic developments.

The startup develops biopharmaceuticals by creating production cell lines and formulating drug substances and finished drugs tailored to patient needs. This approach enables the delivery of personalized medicines, addressing the lack of access to customized treatment options for patients.

The startup has developed a target-identification and drug-discovery platform that utilizes patient-derived and genetically engineered neural cell types to create specialized cell-based assays. This technology aims to facilitate the development of effective treatments for neurological disorders, addressing the significant unmet medical needs in this area.

Cellevolve Bio develops and commercializes cell therapies to treat various diseases by utilizing advanced cellular engineering techniques. The company focuses on addressing the limitations of current treatment options, providing targeted and effective solutions for patients with unmet medical needs.

Enoda utilizes high-throughput screening and systems immunology to engineer cell therapies that enhance the therapeutic potential of cells by mapping underexplored biological pathways. The company addresses the limitations of traditional cell therapy development, which often focuses narrowly on known receptors and cell types, by creating optimized cell phenotypes for a broader range of diseases.

The startup develops optimized parental cells for the production of stem cell exosomes, which have superior proliferation and secretion capabilities. This technology enables mass production of exosomes, providing a scalable solution for targeting incurable diseases.